The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis

Zhang, Min; Meng, Lei; Zhang, Zhaoxuan; Wu, Jing; Chen, Xi; Wang, Yuejing; He, Jie

doi:10.1186/s12920-022-01402-w

Cited by 5 publications

(6 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Meanwhiles, our study revealed that OSBPL3 were associated with the T and N stage of CRC, it's similar to Hao's study. Furthermore, Zhang's research suggests that CRC samples with high OSBPL3 expression exhibit more KRAS mutations, which is consistent with our findings [ 31 ]. However, these results indicated the expression of OSBPL3 had changed in CRC.…”

Section: Discussionsupporting

confidence: 92%

Prognostic and biological function value of OSBPL3 in colorectal cancer analyzed by multi-omic data analysis

Wang

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

Background Colorectal cancer (CRC) is one of the most common malignancies in the world. This study proposes to reveal prognostic biomarkers for the prognosis and treatment of CRC patients. Methods Differential analysis of OSBPL3 was performed in pan-cancer, and the correlation between clinical stage and OSBPL3 was analyzed. Multiple omics analysis was used to compare the relationship between survival of patients and copy number variation, single nucleotide variant, and methylation status. Survival differences between high and low OSBPL3 expression groups were analyzed. Differentially expressed genes (DEGs) between high and low OSBPL3 expression groups were obtained, and functional enrichment analysis was implemented. Correlations between immune cells and OSBPL3 was analyzed. Drug sensitivity between the two OSBPL3 expression groups was compared. Moreover, the expression of OSBPL3 was verified by immunohistochemistry and real-time quantitative PCR. Results OSBPL3 was differentially expressed in 13 tumors and had some correlations with T and N stages. OSBPL3 expression was regulated by methylation and higher OSBPL3 expression was associated with poorer prognosis in CRC. 128 DEGs were obtained and they were mainly involved in signaling receptor activator activity, aspartate and glutamate metabolism. T cell gamma delta and T cell follicular helper were significantly different in the high and low OSBPL3 expression groups. Moreover, OSBPL3 showed negative correlations with multiple drugs. OSBPL3 was significantly upregulated in CRC samples compared to normal samples. Conclusions A comprehensive analysis demonstrated that OSBPL3 had potential prognostic value, and guiding significance for CRC chemotherapeutic.

show abstract

Section: Discussionsupporting

confidence: 92%

Prognostic and biological function value of OSBPL3 in colorectal cancer analyzed by multi-omic data analysis

Wang

et al. 2023

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

“…The most frequent mutation among our patients was c.35G>T p.Gly12Val (32.56%), followed by c.35G>A p.Gly12Asp (20.93%). These two KRAS mutations in codon 12, as well as the codon 13 c.38G>A (p.Gly13Asp) mutation, are the most common mutations among the European population as G12D and G12V are vying for the top spot [ 28 , 29 , 30 , 31 ]. The poor prognosis associated with exon 2 KRAS mutations is well documented, but the prognostic or predictive value of mutations in codons 12 and 13 remains a subject of debate.…”

Section: Discussionmentioning

confidence: 99%

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer

Radanova

Mihaylova

Stoyanov

et al. 2023

IJMS

View full text Add to dashboard Cite

RAS somatic variants are predictors of resistance to anti-EGFR therapy for colorectal cancer (CRC) and affect the outcome of the disease. Our study aimed to evaluate the frequency of RAS, with a focus on KRAS variants, and their association with tumor location and some clinicopathological characteristics in Bulgarian CRC patients. We prospectively investigated 236 patients with advanced and metastatic CRC. Genomic DNA was extracted from FFPE tumor tissue samples, and commercially available kits were used to detect RAS gene somatic mutations via real-time PCR. A total of 115 (48.73%) patients tested positive for RAS mutations, with 106 (44.92%) testing positive for KRAS mutations. The most common mutation in exon 2 was c.35G>T p.Gly12Val (32.56%). We did not find a significant difference in KRAS mutation frequency according to tumor location. However, patients with a mutation in exon 4 of KRAS were 3.23 times more likely to have a tumor in the rectum than in other locations (95% CI: 1.19–8.72, p = 0.021). Studying the link between tumor location and KRAS mutations in exon 4 is crucial for better characterizing CRC patients. Further research with larger cohorts, especially in rectal cancer patients, could provide valuable insights for patient follow-up and treatment selection.

show abstract

“…17 Previous studies showed that Ki67 is a prognostic marker in many tumors, such as colorectal cancer, breast cancer, lymphoma, prostate cancer, and laryngeal cancer. [18][19][20][21][22] Additionally, the Ki67 labeling index (LI) of SGC (46.1% ± 3.0%) was higher than that of normal conjunctiva (6.8% ± 32.3%). 23 Similarly, high Ki67 expression was associated with poor outcomes in eyelid SGC recurrence and lymph node metastasis.…”

Section: Discussionmentioning

confidence: 99%

“…Ki67 is a potent marker for cellular proliferation, and its primary function involves acting as a biosurfactant that promotes the dispersion of chromosomes during mitosis 17 . Previous studies showed that Ki67 is a prognostic marker in many tumors, such as colorectal cancer, breast cancer, lymphoma, prostate cancer, and laryngeal cancer 18–22 . Additionally, the Ki67 labeling index (LI) of SGC (46.1% ± 3.0%) was higher than that of normal conjunctiva (6.8% ± 32.3%) 23 .…”

Section: Discussionmentioning

confidence: 99%

Development and validation of a nomogram to predict the recurrence of eyelid sebaceous gland carcinoma

Nie

Geng

et al. 2023

Cancer Medicine

View full text Add to dashboard Cite

PurposeEyelid sebaceous gland carcinoma (SGC) is a malignancy with fatal risk, high recurrence rate, and pagetoid spread. Thus, recurrence risk prediction and prompt treatment are extremely important. This study aimed to develop a nomogram to predict SGC recurrence based on potential risk factors.MethodsWe conducted a retrospective study to train and test a nomogram based on the clinical data of 391 patients across our hospital (304) and other grass‐roots hospitals (87). After Cox regression, predictors included in the nomogram were selected, and sensitivity, specificity, concordance index (C‐index), etc., were calculated to test their discrimination ability.ResultsAfter a median follow‐up period of 4.12 years, SGC recurred in 52 (17.11%) patients. The 1‐, 2‐, and 5‐year recurrence‐free survival rates were 88.3%, 85.4%, and 81.6%, respectively. We examined five risk factors, such as lymph node metastasis at initial diagnosis (hazard ratio [HR], 2.260; 95% confidence interval [CI], 1.021–5.007), Ki67 (HR, 1.036; 95% CI, 1.020–1.052), histology differentiation degree (HR, 2.274; 95% CI, 1.063–4.865), conjunctival pagetoid infiltration (HR, 2.100; 95% CI, 1.0058–4.167), and orbital involvement (HR, 4.764; 95% CI, 1.436–15.803). The model had good discrimination in both internal and external test sets. The model had good discrimination in both internal and external test sets. The sensitivity of the internal test and external test set were 0.722 and 0.806, respectively, and specificity of the internal test and external test set were 0.886 and 0.893, respectively.ConclusionWe examined the potential risk factors for eyelid SGC recurrence and constructed a nomogram, which complements the TNM system in terms of prediction, indicating that our nomogram has the potential to reach clinical significance. This nomogram has the potential to assist healthcare practitioners in promptly detecting patients who are at an elevated risk and in tailoring clinical interventions to meet their individualized needs.

show abstract

The relationships of OSBPL3 expression with KI-67 expression and KRAS mutations in CRC: implications for diagnosis and prognosis

Cited by 5 publications

References 45 publications

Prognostic and biological function value of OSBPL3 in colorectal cancer analyzed by multi-omic data analysis

Prognostic and biological function value of OSBPL3 in colorectal cancer analyzed by multi-omic data analysis

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer

Development and validation of a nomogram to predict the recurrence of eyelid sebaceous gland carcinoma

Contact Info

Product

Resources

About